FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge

Feline immunodeficiency virus: In vivo protection remains elusive A vaccine candidate for feline immunodeficiency virus elicits strong immunological reaction in vitro, but no protection to live cats. The feline analog to human immunodeficiency virus, FIV shares a similar infection paradigm and has o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Craig Miller, Mauren Emanuelli, Elizabeth Fink, Esther Musselman, Ryan Mackie, Ryan Troyer, John Elder, Sue VandeWoude
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/205cd096895a417caabb9e554d669d75
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:205cd096895a417caabb9e554d669d75
record_format	dspace
spelling	oai:doaj.org-article:205cd096895a417caabb9e554d669d752021-12-02T16:06:40ZFIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge10.1038/s41541-018-0051-y2059-0105https://doaj.org/article/205cd096895a417caabb9e554d669d752018-04-01T00:00:00Zhttps://doi.org/10.1038/s41541-018-0051-yhttps://doaj.org/toc/2059-0105Feline immunodeficiency virus: In vivo protection remains elusive A vaccine candidate for feline immunodeficiency virus elicits strong immunological reaction in vitro, but no protection to live cats. The feline analog to human immunodeficiency virus, FIV shares a similar infection paradigm and has only one partially effective vaccine. A US team, led by Colorado State University’s Susan VandeWoude, immunized cats using a complex of an FIV surface protein and a feline cell-surface protein known to facilitate FIV’s entry into immune cells. Tissue culture assays yielded promising results; however, this did not translate to live-animal protection. The researchers highlighted multiple factors that could explain the lack of success, including circulatory pro-infection factors, and immune responses generated against vaccine by-products rather than intended targets. While the vaccine candidate failed, the research provides invaluable guidance for future efforts into FIV vaccination with implications for HIV vaccine trials.Craig MillerMauren EmanuelliElizabeth FinkEsther MusselmanRyan MackieRyan TroyerJohn ElderSue VandeWoudeNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 3, Iss 1, Pp 1-12 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Craig Miller Mauren Emanuelli Elizabeth Fink Esther Musselman Ryan Mackie Ryan Troyer John Elder Sue VandeWoude FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge
description	Feline immunodeficiency virus: In vivo protection remains elusive A vaccine candidate for feline immunodeficiency virus elicits strong immunological reaction in vitro, but no protection to live cats. The feline analog to human immunodeficiency virus, FIV shares a similar infection paradigm and has only one partially effective vaccine. A US team, led by Colorado State University’s Susan VandeWoude, immunized cats using a complex of an FIV surface protein and a feline cell-surface protein known to facilitate FIV’s entry into immune cells. Tissue culture assays yielded promising results; however, this did not translate to live-animal protection. The researchers highlighted multiple factors that could explain the lack of success, including circulatory pro-infection factors, and immune responses generated against vaccine by-products rather than intended targets. While the vaccine candidate failed, the research provides invaluable guidance for future efforts into FIV vaccination with implications for HIV vaccine trials.
format	article
author	Craig Miller Mauren Emanuelli Elizabeth Fink Esther Musselman Ryan Mackie Ryan Troyer John Elder Sue VandeWoude
author_facet	Craig Miller Mauren Emanuelli Elizabeth Fink Esther Musselman Ryan Mackie Ryan Troyer John Elder Sue VandeWoude
author_sort	Craig Miller
title	FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge
title_short	FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge
title_full	FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge
title_fullStr	FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge
title_full_unstemmed	FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge
title_sort	fiv vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/205cd096895a417caabb9e554d669d75
work_keys_str_mv	AT craigmiller fivvaccinewithreceptorepitopesresultsinneutralizingantibodiesbutdoesnotconferresistancetochallenge AT maurenemanuelli fivvaccinewithreceptorepitopesresultsinneutralizingantibodiesbutdoesnotconferresistancetochallenge AT elizabethfink fivvaccinewithreceptorepitopesresultsinneutralizingantibodiesbutdoesnotconferresistancetochallenge AT esthermusselman fivvaccinewithreceptorepitopesresultsinneutralizingantibodiesbutdoesnotconferresistancetochallenge AT ryanmackie fivvaccinewithreceptorepitopesresultsinneutralizingantibodiesbutdoesnotconferresistancetochallenge AT ryantroyer fivvaccinewithreceptorepitopesresultsinneutralizingantibodiesbutdoesnotconferresistancetochallenge AT johnelder fivvaccinewithreceptorepitopesresultsinneutralizingantibodiesbutdoesnotconferresistancetochallenge AT suevandewoude fivvaccinewithreceptorepitopesresultsinneutralizingantibodiesbutdoesnotconferresistancetochallenge
_version_	1718384890257342464

FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge

Ejemplares similares